References

1. Radi_sauskas R, Kuzmickien_e I, Milinavi_cien_e E, Everatt R. Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. Medicina (Kaunas). 2016;52:89e98.
2. Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a metaanalysis of prospective studies. Cancer Causes Control.2015; 26:257e268.
3. Isles CG, Hole DJ, Gillis CR, Hawthorne VM, Lever AF. Plasmacholesterol, coronary heart disease, and cancer in the Renfrewand Paisley survey. BMJ. 1989;298:920e924.
4. Cengiz O, Kocer B, Su¨rmeli S, Santicky MJ, Soran A. Arepretreatment serum albumin and cholesterol levels prognostictools in patients with colorectal carcinoma? Med Sci Monit.2006; 12:CR240eCR247.
5. Yang Y, Mauldin PD, Ebeling M, et al. Effect of metabolicsyndrome and its components on recurrence and survival incolon cancer patients. Cancer. 2013;119:1512e1520.
6. Chi PD, Liu W, Chen H, et al. High-density lipoproteincholesterol is a favorable prognostic factor and negativelycorrelated with C-reactive protein level in non-small cell lungcarcinoma. PLoS One. 2014;9:e91080.
7. Li AJ, Elmore RG, Chen IY, Karlan BY. Serum low-density lipoproteinlevels correlate with survival in advanced stageepithelial ovarian cancers. Gynecol Oncol. 2010;116:78e81.
8. You J, Liu WY, Zhu GQ, et al. Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget. 2015;6:19880e19890.
9. Fan Y, Ding X, Wang J, et al. Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs. Int J Biol Markers.2015;30:e200ee207.
10. Liu YY, Lin SJ, Chen YY, et al. High-density lipoproteincholesterol as a predictor of poor survival in patients with nasopharyngeal carcinoma. Oncotarget. 2016;7:42978e42987.
11. Bahl M, Ennis M, Tannock IF, et al. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res Treat. 2005;94:135e144
12. Panagiotakos DB, Pitsavos C, Polychronopoulos E, et al. Total cholesterol and body mass index in relation to 40-year cancer mortality (the Corfu cohort of the seven countries study). Cancer Epidemiol Biomarkers Prev. 2005;14:1797e1801
13. T€ornberg SA, Holm LE, Carstensen JM, Eklund GA. Cancerincidence and cancer mortality in relation to serum cholesterol.J Natl Cancer Inst. 1989;81:1917e1921.
14. Han CZ, Du LL, Liu XY, Jing JX, Zhao XW, Tian BG. Study on the correlation between serum leptin and lipids level and breast cancer. Yingyang Xuebao. 2005;5:32–35.
15. Chang SJ, Hou MF, Tsai SM, Wu SH, Hou LA, Ma H, Shann TY, Wu SH, Tsai LY. The association between lipid profiles and breast cancer among Taiwanese women. Clin Chem Lab Med. 2007;45:1219–1223. [PubMed]
16. Rose G, Blackburn H, Keys A, Taylor HL, Kannel WB, Paul O, Reid DD, Stamler J. Colon cancer and blood-cholesterol. 1974;1:181–183. [PubMed]
17. Williams RR, Sorlie PD, Feinleib M, McNamara PM, Kannel WB, Dawber TR. Cancer incidence by levels of cholesterol. 1981;245:247–252. [PubMed]
18. Kitahara CM, Berrington de González A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29:1592–1598. [PMC free article][PubMed]
19. Chung YW, Han DS, Park YK, Son BK, Paik CH, Lee HL, Jeon YC, Sohn JH. Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. Dig Liver Dis. 2006;38:668–672. [PubMed].

Corresponding Author

Chitra Raghavan

Regional Institute of Ophthalmology, Thiruvananthapuram-695001, Kerala, India

Phone number: +91-7012733798, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.